Medford, A. J., Dubash, T. D., Juric, D., Spring, L., Niemierko, A., Vidula, N., . . . Bardia, A. (2019). Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol.
Dyfyniad Arddull ChicagoMedford, Arielle J., et al. "Blood-based Monitoring Identifies Acquired and Targetable Driver HER2 Mutations in Endocrine-resistant Metastatic Breast Cancer." NPJ Precis Oncol 2019.
Dyfyniad MLAMedford, Arielle J., et al. "Blood-based Monitoring Identifies Acquired and Targetable Driver HER2 Mutations in Endocrine-resistant Metastatic Breast Cancer." NPJ Precis Oncol 2019.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.